No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

by Colhoun, Helen M., Ginsberg, Henry N., Robinson, Jennifer G., Leiter, Lawrence A., Müller-Wieland, Dirk, Henry, Robert R., Cariou, Bertrand, Baccara-Dinet, Marie T., Pordy, Robert, Merlet, Laurence, Eckel, Robert H.
Published 2016